Pay in 4 interest-free payments of $7.42 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
Wegovy's cardiovascular indication rests on a large outcomes trial described in its label, in which 8,803 patients were exposed to Wegovy for a median of 37.3 months and 8,801 to placebo for a median of 38.6 months, with a primary endpoint of time to first cardiovascular death, nonfatal myocardial infarction or nonfatal stroke
Safety and efficacy of focused ultrasound induced blood-brain barrier opening, an integrative review of animal and human studies
For many, Ozempic and other GLP-1 medications have opened the door to new possibilities
The Precision Peptide Genetic Test ($298) maps 14 metabolic pathways and 49 peptides to inform your personalized protocol
May offer supportive benefits for patients with weight challenges related to PCOS insulin resistance, depending on individual health factors
US$ 22.18
US$ 25.57
US$ 20.56
US$ 26.64
US$ 23.27
US$ 20.17
